Secondly, although CSF1R mRNA expression level seems to correlate with the response to narazaciclib in a selection of AML cell lines (Fig. 1B and Supplemental Fig. S8) and AML-PDX models (Fig. 3C), a few AML cell lines (OCI-AML-3, NOMO-1 and THP-1) with relatively high CSF1R expression showed suboptimal response to narazaciclib. The gene discussed is CSF1R; the disease is acute myeloid leukemia.